Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.
You may also be interested in...
GAO Tracks Decline In ESA Use Following Regulatory Changes
A Government Accountability Office report finds that use of erthryopoiesis-stimulating agents in dialysis decreased 31% from 2007 to the end of 2011 after Medicare’s bundled dialysis payment was changed to include drugs and FDA revised dosing recommendations.
ESRD Market Snapshot: The Price Has To Be Right
The market for kidney disease drugs is under pressure from Medicare cost containment policies. However, there is still room for new drugs – if they can demonstrate a cost-savings benefit.
Amgen Hits Another Emerging Market Target With $700M Turkish Deal
Fulfilling its pledge to dramatically expand internationally, Amgen sealed a deal to purchase coveted drugmaker Mustafa Nevzat, gaining a foothold in Turkey. Meanwhile, its pipeline progresses with no clear winners to help cushion the blows to the company’s ESAs.